
### [MONDO:0020045](http://purl.obolibrary.org/obo/MONDO_0020045)
**Label:** autosomal recessive cerebellar ataxia due to a DNA repair defect

**Subclasses:** [MONDO:0014399](http://purl.obolibrary.org/obo/MONDO_0014399) (PCNA-related progressive neurodegenerative photosensitivy syndrome), [MONDO:0018996](http://purl.obolibrary.org/obo/MONDO_0018996) (spinocerebellar ataxia with axonal neuropathy type 2), [MONDO:0008690](http://purl.obolibrary.org/obo/MONDO_0008690) (xeroderma pigmentosum, autosomal dominant, mild), [MONDO:0012531](http://purl.obolibrary.org/obo/MONDO_0012531) (xeroderma pigmentosum group B), [MONDO:0010210](http://purl.obolibrary.org/obo/MONDO_0010210) (xeroderma pigmentosum group A), [MONDO:0019600](http://purl.obolibrary.org/obo/MONDO_0019600) (xeroderma pigmentosum), [MONDO:0016354](http://purl.obolibrary.org/obo/MONDO_0016354) (xeroderma pigmentosum-Cockayne syndrome complex), [MONDO:0008840](http://purl.obolibrary.org/obo/MONDO_0008840) (ataxia telangiectasia), [MONDO:0014084](http://purl.obolibrary.org/obo/MONDO_0014084) (ataxia with oculomotor apraxia type 3), [MONDO:0008841](http://purl.obolibrary.org/obo/MONDO_0008841) (ataxia-telangiectasia with generalized skin pigmentation and early death), [MONDO:0008842](http://purl.obolibrary.org/obo/MONDO_0008842) (ataxia with oculomotor apraxia type 1), [MONDO:0010213](http://purl.obolibrary.org/obo/MONDO_0010213) (xeroderma pigmentosum group E), [MONDO:0011457](http://purl.obolibrary.org/obo/MONDO_0011457) (ataxia-telangiectasia-like disorder), [MONDO:0010214](http://purl.obolibrary.org/obo/MONDO_0010214) (xeroderma pigmentosum variant type), [MONDO:0010211](http://purl.obolibrary.org/obo/MONDO_0010211) (xeroderma pigmentosum group C), [MONDO:0012764](http://purl.obolibrary.org/obo/MONDO_0012764) (RIDDLE syndrome), [MONDO:0010212](http://purl.obolibrary.org/obo/MONDO_0010212) (xeroderma pigmentosum group D), [MONDO:0011801](http://purl.obolibrary.org/obo/MONDO_0011801) (spinocerebellar ataxia type 1 with axonal neuropathy), [MONDO:0010215](http://purl.obolibrary.org/obo/MONDO_0010215) (xeroderma pigmentosum group F), [MONDO:0010216](http://purl.obolibrary.org/obo/MONDO_0010216) (xeroderma pigmentosum group G), [MONDO:0011623](http://purl.obolibrary.org/obo/MONDO_0011623) (spinocerebellar ataxia, autosomal recessive 1), 

**Corr. equiv. classes:** [Orphanet:100](http://www.orpha.net/ORDO/Orphanet_100), [OMIM:194400](http://purl.obolibrary.org/obo/OMIM_194400), [Orphanet:438134](http://www.orpha.net/ORDO/Orphanet_438134), [OMIM:278750](http://purl.obolibrary.org/obo/OMIM_278750), [OMIM:208900](http://purl.obolibrary.org/obo/OMIM_208900), [OMIM:610651](http://purl.obolibrary.org/obo/OMIM_610651), [Orphanet:220295](http://www.orpha.net/ORDO/Orphanet_220295), [OMIM:208920](http://purl.obolibrary.org/obo/OMIM_208920), [Orphanet:420741](http://www.orpha.net/ORDO/Orphanet_420741), [Orphanet:910](http://www.orpha.net/ORDO/Orphanet_910), [OMIM:611943](http://purl.obolibrary.org/obo/OMIM_611943), [OMIM:606002](http://purl.obolibrary.org/obo/OMIM_606002), [OMIM:278730](http://purl.obolibrary.org/obo/OMIM_278730), [OMIM:607250](http://purl.obolibrary.org/obo/OMIM_607250), [OMIM:278780](http://purl.obolibrary.org/obo/OMIM_278780), [Orphanet:1168](http://www.orpha.net/ORDO/Orphanet_1168), [OMIM:278760](http://purl.obolibrary.org/obo/OMIM_278760), [Orphanet:251347](http://www.orpha.net/ORDO/Orphanet_251347), [Orphanet:64753](http://www.orpha.net/ORDO/Orphanet_64753), [OMIM:615217](http://purl.obolibrary.org/obo/OMIM_615217), [OMIM:208910](http://purl.obolibrary.org/obo/OMIM_208910), [OMIM:278700](http://purl.obolibrary.org/obo/OMIM_278700), [OMIM:278740](http://purl.obolibrary.org/obo/OMIM_278740), [OMIM:604391](http://purl.obolibrary.org/obo/OMIM_604391), [OMIM:615919](http://purl.obolibrary.org/obo/OMIM_615919), [Orphanet:90342](http://www.orpha.net/ORDO/Orphanet_90342), [Orphanet:94124](http://www.orpha.net/ORDO/Orphanet_94124), [OMIM:278720](http://purl.obolibrary.org/obo/OMIM_278720), 

**Class expressions from DL-Learner:**

- [HP:0000504](http://purl.obolibrary.org/obo/HP_0000504) (Abnormality of vision) and [HP:0001029](http://purl.obolibrary.org/obo/HP_0001029) (Poikiloderma) 62.50%
- [HP:0001029](http://purl.obolibrary.org/obo/HP_0001029) (Poikiloderma) and [HP:0004334](http://purl.obolibrary.org/obo/HP_0004334) (Dermal atrophy) and [HP:0012649](http://purl.obolibrary.org/obo/HP_0012649) (Increased inflammatory response) 62.50%
- [HP:0001029](http://purl.obolibrary.org/obo/HP_0001029) (Poikiloderma) and [HP:0004334](http://purl.obolibrary.org/obo/HP_0004334) (Dermal atrophy) and [HP:0012647](http://purl.obolibrary.org/obo/HP_0012647) (Abnormal inflammatory response) 62.50%
- [HP:0000504](http://purl.obolibrary.org/obo/HP_0000504) (Abnormality of vision) and [HP:0001029](http://purl.obolibrary.org/obo/HP_0001029) (Poikiloderma) and [HP:0012649](http://purl.obolibrary.org/obo/HP_0012649) (Increased inflammatory response) 62.50%
- [HP:0000504](http://purl.obolibrary.org/obo/HP_0000504) (Abnormality of vision) and [HP:0001029](http://purl.obolibrary.org/obo/HP_0001029) (Poikiloderma) and [HP:0012647](http://purl.obolibrary.org/obo/HP_0012647) (Abnormal inflammatory response) 62.50%
- [HP:0000504](http://purl.obolibrary.org/obo/HP_0000504) (Abnormality of vision) and [HP:0001029](http://purl.obolibrary.org/obo/HP_0001029) (Poikiloderma) and [HP:0012638](http://purl.obolibrary.org/obo/HP_0012638) (Abnormality of nervous system physiology) 62.50%
- [HP:0000504](http://purl.obolibrary.org/obo/HP_0000504) (Abnormality of vision) and [HP:0001029](http://purl.obolibrary.org/obo/HP_0001029) (Poikiloderma) and [HP:0004334](http://purl.obolibrary.org/obo/HP_0004334) (Dermal atrophy) 62.50%
- [HP:0001029](http://purl.obolibrary.org/obo/HP_0001029) (Poikiloderma) and [HP:0004334](http://purl.obolibrary.org/obo/HP_0004334) (Dermal atrophy) and [HP:0012638](http://purl.obolibrary.org/obo/HP_0012638) (Abnormality of nervous system physiology) and [HP:0012649](http://purl.obolibrary.org/obo/HP_0012649) (Increased inflammatory response) 62.50%
- [HP:0001029](http://purl.obolibrary.org/obo/HP_0001029) (Poikiloderma) and [HP:0004334](http://purl.obolibrary.org/obo/HP_0004334) (Dermal atrophy) and [HP:0012638](http://purl.obolibrary.org/obo/HP_0012638) (Abnormality of nervous system physiology) and [HP:0012647](http://purl.obolibrary.org/obo/HP_0012647) (Abnormal inflammatory response) 62.50%
- [HP:0001029](http://purl.obolibrary.org/obo/HP_0001029) (Poikiloderma) and [HP:0004334](http://purl.obolibrary.org/obo/HP_0004334) (Dermal atrophy) and [HP:0012374](http://purl.obolibrary.org/obo/HP_0012374) (Abnormality of the globe) and [HP:0012649](http://purl.obolibrary.org/obo/HP_0012649) (Increased inflammatory response) 62.50%
- [HP:0001029](http://purl.obolibrary.org/obo/HP_0001029) (Poikiloderma) and [HP:0004334](http://purl.obolibrary.org/obo/HP_0004334) (Dermal atrophy) and [HP:0012374](http://purl.obolibrary.org/obo/HP_0012374) (Abnormality of the globe) and [HP:0012647](http://purl.obolibrary.org/obo/HP_0012647) (Abnormal inflammatory response) 62.50%
- [HP:0001029](http://purl.obolibrary.org/obo/HP_0001029) (Poikiloderma) and [HP:0004334](http://purl.obolibrary.org/obo/HP_0004334) (Dermal atrophy) and [HP:0012373](http://purl.obolibrary.org/obo/HP_0012373) (Abnormal eye physiology) and [HP:0012649](http://purl.obolibrary.org/obo/HP_0012649) (Increased inflammatory response) 62.50%
- [HP:0001029](http://purl.obolibrary.org/obo/HP_0001029) (Poikiloderma) and [HP:0004334](http://purl.obolibrary.org/obo/HP_0004334) (Dermal atrophy) and [HP:0012373](http://purl.obolibrary.org/obo/HP_0012373) (Abnormal eye physiology) and [HP:0012647](http://purl.obolibrary.org/obo/HP_0012647) (Abnormal inflammatory response) 62.50%
- [HP:0001029](http://purl.obolibrary.org/obo/HP_0001029) (Poikiloderma) and [HP:0004334](http://purl.obolibrary.org/obo/HP_0004334) (Dermal atrophy) and [HP:0012372](http://purl.obolibrary.org/obo/HP_0012372) (Abnormal eye morphology) and [HP:0012649](http://purl.obolibrary.org/obo/HP_0012649) (Increased inflammatory response) 62.50%
- [HP:0001029](http://purl.obolibrary.org/obo/HP_0001029) (Poikiloderma) and [HP:0004334](http://purl.obolibrary.org/obo/HP_0004334) (Dermal atrophy) and [HP:0012372](http://purl.obolibrary.org/obo/HP_0012372) (Abnormal eye morphology) and [HP:0012647](http://purl.obolibrary.org/obo/HP_0012647) (Abnormal inflammatory response) 62.50%


